Sai Parenteral's

** Shares of India's Sai Parenterals SAIP.NS rise as much as 9.7% to 578.95 rupees

** Diversified pharmaceutical formulations co says Australian unit Noumed Pharmaceuticals renews OTC medicines supply agreement with a leading Australian pharmacy network for three years

** Adds agreement is valued at AUD 30 million, with expanded product portfolio

** More than 521,551 shares change hands, about 4.5x the 30-day average volume - LSEG compiled data

** Stock up 32.3% since listing on April 2, 2026

(Reporting by Payel Das in Bengaluru)

(([email protected]))

Sai Parenterals said its Australian subsidiary, Noumed Pharmaceuticals, had renewed a three-year OTC medicines supply agreement with one of Australia's leading pharmacy networks, valued at AUD30 million, or about ₹204 crore. The agreement covered an expanded product portfolio and provided for new product development and line extensions, with Noumed retaining responsibility for registrations, compliance, sourcing, inventory and nationwide distribution. It followed a 7½-year AUD202 million agreement renewed in July, taking Noumed's contracted Australian OTC supply to AUD232 million. Sai Parenterals reported consolidated revenue of about ₹381 crore for FY26, while volumes under the agreements were largely sourced from third-party manufacturers.

Powered by Tijori

Sai Parenterals’ subsidiary Noumed Pharmaceuticals renewed a three-year OTC medicines supply agreement with an Australian pharmacy network, with projected orders worth AUD30m, or about ₹204 crore. The contract took effect on 24 August 2026 and covered an expanded product portfolio. The counterparty was described as one of Australia’s leading multi-billion-dollar pharmacy chains but was not named. Sai Parenterals generated consolidated revenue of about ₹381 crore in FY26, with CDMO activities accounting for 63% of net revenue.

Powered by Tijori

Aug 25 (Reuters) - Sai Parenteral's Ltd SAIP.NS:

• NOUMED PHARMACEUTICALS RENEWS 3-YEAR OTC SUPPLY AGREEMENT VALUED AT A$30 MILLION

Source text: ID:nBSE8N8mmS

Further company coverage: SAIP.NS

(([email protected];))

Sai Parenterals reported consolidated revenue from operations of ₹178.7 crore and profit after tax of ₹7.9 crore for the June 2026 quarter, compared with ₹33.4 crore and ₹1.4 crore a year earlier. The company had raised ₹285 crore in an April IPO to support a ₹440 crore capex programme. The board approved redirecting ₹83.83 crore of the IPO proceeds from upgrades at Units I and II to acquire 60% of Saicriti Pharma, which was developing a critical-care sterile-injectables facility in Hyderabad with an estimated cost of ₹214.96 crore. It also approved using the R&D allocation for a 60% cash acquisition of Prathyak Laboratories, an R&D platform at Genome Valley; the filing gave the allocation as ₹18.02 crore and the acquisition cost as ₹15 crore. Sai Parenterals approved a wholly owned US subsidiary and shareholder votes on material related-party transactions involving Sai Singapore and Noumed Pharmaceuticals. Anil Kumar Karusala and Vijitha Gorrepati were reappointed as managing and whole-time directors respectively, while Kunal Kakumanu was appointed executive director; Aruna Karusala resigned as a non-executive director and Shivali Aggarwal as company secretary, with her departure due by 12 October.

Powered by Tijori

Sai Parenterals’ board approved, subject to shareholder consent, a reallocation of ₹101.86 crore of IPO proceeds. ₹83.83 crore originally earmarked for upgrading Units I and II was directed towards acquiring 60% of Saicriti Pharma, which was developing a sterile-injectables facility at Gummadidala, Hyderabad, while ₹18.02 crore intended for an R&D centre was directed towards a 60% stake in Prathyak Laboratories. Prathyak had an R&D platform at Genome Valley and a portfolio of 124 products under development, with both acquisitions targeted for completion before 30 October 2026. The reallocation altered a ₹440 crore expansion programme approved in September 2025 for EU-GMP upgrades, an R&D centre and an Adelaide facility. The board also approved a US step-down subsidiary, proposed related-party transactions with Sai Singapore and Noumed, and accepted the resignations of a non-executive director and the company secretary. Consolidated revenue for the June quarter was ₹178.67 crore, against ₹33.39 crore a year earlier, while profit after tax was ₹7.92 crore versus ₹1.42 crore.

Powered by Tijori

** Shares of Sai Parenteral's SAIP.NS rise as much as 15.3% to a record high of 706 rupees

** Stock gains after company says its subsidiary, Noumed Pharmaceuticals, has renewed an over-the-counter medicine supply agreement with Australia's leading pharmacy networks

** Says contract is valued at about 13 billion rupees($136.88 million)

** More than 42,587 shares change hands vs 30-day avg of 345,845 shares

** Stock up 57.5% since its listing in February

(Reporting by Payel Das in Bengaluru)

(([email protected]))

Sai Parenterals Ltd's subsidiary, Noumed Pharmaceuticals Pty Ltd, has signed an exclusive long-term contract with Australia's largest pharmacy network to supply over-the-counter medicines, the company said on Tuesday. The deal is valued at Australian dollars 202 million, or about 1,300 crore rupees, and will run for seven-and-a-half years with an option to extend by an additional three years upon mutual consent. The agreement, which took effect on July 1, marks a significant deepening of the Hyderabad-based drugmakers presence in the Australian market after its acquisition of Noumed last November. At roughly 3.4 times the companys reported consolidated revenue of 381 crore rupees for the financial year just ended, the contract provides transformational scale and multi-year revenue visibility.

Powered by Tijori

July 1 (Reuters) - Sai Parenteral's Ltd SAIP.NS:

• AUSTRALIAN SUBSIDIARY RENEWS ITS OTC SUPPLY AGREEMENT WITH AUSTRALIA'S LEADING PHARMACY NETWORKS

• DEAL VALUED AT AUD 202 MILLION

Source text: ID:nBSE2ZPZvv

Further company coverage: SAIP.NS

(([email protected];))

April 20 (Reuters) - Sai Parenteral's Ltd SAIP.NS:

• SAI PARENTERAL'S - APPROVES LOAN UP TO AUD 1.75 MILLION TO SAI SINGAPORE

Source text: ID:nBSE7KR6R2

Further company coverage: SAIP.NS

(([email protected];;))